HIV prevention may be revolutionized by a breakthrough that eliminates the daily pill burden that has limited adherence for decades. The shift from daily oral medications to twice-yearly injections could dramatically expand protection for high-risk populations who struggle with consistent medication-taking behaviors. Lenacapavir operates through a novel capsid inhibition mechanism that blocks HIV-1 replication at the viral assembly stage, administered via subcutaneous injection every six months. Clinical trials demonstrate superior prevention efficacy compared to background HIV incidence rates across diverse populations and gender identities using counterfactual design methodology. The drug's unique mechanism targets a different viral pathway than existing antiretroviral classes, potentially preserving treatment options if resistance develops. Common adverse events center on injection-site reactions including nodules, pain, and localized swelling, though these appear manageable in clinical settings. This represents a paradigm shift in HIV prevention strategy, moving from daily adherence-dependent oral prophylaxis to long-acting injectable protection. The extended dosing interval addresses a critical gap for individuals who cannot maintain consistent oral PrEP regimens due to lifestyle factors, stigma, or adherence challenges. While lenacapavir shows moderate cytochrome P450 inhibition requiring drug interaction monitoring, it requires no renal or hepatic dose adjustments, simplifying clinical management. The twice-yearly dosing could transform prevention accessibility, particularly for populations with limited healthcare access or those seeking discrete protection methods.